Analysts Set Heska Corp. (HSKA) Price Target at $55.83
Heska Corp. (NASDAQ:HSKA) has been given a consensus rating of “Buy” by the six research firms that are currently covering the firm. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $55.83.
Several research firms have recently commented on HSKA. B. Riley reissued a “neutral” rating and issued a $53.00 price objective on shares of Heska Corp. in a report on Wednesday, November 2nd. Zacks Investment Research raised Heska Corp. from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a report on Wednesday, November 2nd. Finally, Gabelli downgraded Heska Corp. from a “buy” rating to a “hold” rating in a report on Thursday, August 4th.
Shares of Heska Corp. (NASDAQ:HSKA) opened at 68.36 on Wednesday. The firm has a market cap of $471.55 million, a P/E ratio of 54.73 and a beta of 0.74. The firm’s 50-day moving average is $56.35 and its 200-day moving average is $47.16. Heska Corp. has a 1-year low of $26.25 and a 1-year high of $68.52.
Heska Corp. (NASDAQ:HSKA) last released its quarterly earnings data on Tuesday, November 1st. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.25 by $0.20. The company earned $33.40 million during the quarter, compared to the consensus estimate of $31.36 million. Heska Corp. had a return on equity of 10.46% and a net margin of 7.55%. The business’s revenue was up 19.3% on a year-over-year basis. On average, analysts anticipate that Heska Corp. will post $1.32 EPS for the current fiscal year.
In other Heska Corp. news, CEO Kevin S. Wilson sold 20,000 shares of the stock in a transaction on Monday, August 29th. The stock was sold at an average price of $51.80, for a total transaction of $1,036,000.00. Following the transaction, the chief executive officer now owns 110,000 shares in the company, valued at approximately $5,698,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jason A. Napolitano sold 5,000 shares of the stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $52.53, for a total value of $262,650.00. The disclosure for this sale can be found here. 15.30% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. MSI Financial Services Inc purchased a new position in Heska Corp. during the third quarter valued at $103,000. Bank of Montreal Can purchased a new position in Heska Corp. during the second quarter valued at $128,000. Acrospire Investment Management LLC boosted its position in Heska Corp. by 786.3% in the second quarter. Acrospire Investment Management LLC now owns 4,396 shares of the company’s stock valued at $163,000 after buying an additional 3,900 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in Heska Corp. by 7.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,853 shares of the company’s stock valued at $180,000 after buying an additional 320 shares during the last quarter. Finally, BlackRock Inc. boosted its position in Heska Corp. by 863.1% in the second quarter. BlackRock Inc. now owns 5,095 shares of the company’s stock valued at $189,000 after buying an additional 4,566 shares during the last quarter. Hedge funds and other institutional investors own 71.80% of the company’s stock.
About Heska Corp.
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
Receive News & Stock Ratings for Heska Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp. and related stocks with our FREE daily email newsletter.